Credit Suisse Sees Downside In Shares Of Salix Pharmaceuticals, Ltd.

By: via Benzinga
Analysts at Credit Suisse initiated coverage on Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) with an Underperform rating and $139 price ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.